2026-04-18T07:50:26Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2222432025-12-05T00:53:02Zcom_2072_1057col_2072_478916col_2072_478917

Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial) Sierra Rodero, Belén Martínez Toledo, Cristina Nadal, Ernest Molina Alejandre, Marta García Campelo, Rosario Gil González, Ángeles Massuti, Bartomeu García Grande, Aránzazu Dómine, Manuel Insa, Amelia Castro Carpeño, Javier de Huidobro Vence, Gerardo Majem, Margarita Martínez Martí, Alex Megias Vazquez, Diego Lobato Alosnos, Daniel Ángel Collazo-Lorduy, Ana Calvo, Virginia Provencio, Mariano Cruz Bermúdez, Alberto Cèl·lules B Immunoteràpia B cells Immunotheraphy Perioperative chemoimmunotherapy has significantly improved survival rates for non-small cell lung cancer (NSCLC). However, current tissue biomarkers remain inadequate, underscoring the need for more sensitive and accessible alternatives to monitor relapse risk. Intratumoral B-cells are increasingly recognized for their role in enhancing immunotherapy outcomes, yet the contribution of peripheral B-cells to immune surveillance remains unexplored. Peripheral B-cell immunophenotypes were analyzed from blood samples (at diagnosis, post-neoadjuvant, and at 6- and 12-months of adjuvant treatment) in 41 stage IIIA NSCLC patients treated with perioperative nivolumab plus chemotherapy, included in the NADIM clinical trial (NCT03081689). Results were correlated with 5-year survival outcomes and validated through unsupervised clustering. An increase in the percentage of total B-cells (CD19+CD20+) and na & iuml;ve B-cells (CD19+CD20+CD24+CD38+CD27-CD10-), along with a reduction in CD20 expression on total B-cells, a decrease in the proportion of memory B-cells (CD19+CD20+CD24+CD38-/lowCD27+) and transitional B-cells (CD19+CD20+CD24++CD38++CD10+), was observed during the time encompassed between the end of neoadjuvant treatment and the posterior 6 months of adjuvant treatment. Higher levels of CD20 expression on total B-cells, along with an increased percentage of memory B-cells, or activated B-cells (CD19+CD20+CD25+), at 6- and 12-months of adjuvant treatment, were associated with increased survival. Conversely, higher levels of a newly described circulating population of CD19+CD20lowCD25lowCD27low B-cells during adjuvant treatment were linked to disease progression. Perioperative nivolumab plus chemotherapy in resectable NSCLC patients induces significant changes in peripheral B-cells. The persistence of circulating memory B-cells during adjuvant treatment might play a crucial role in survival. 2025-07-15T08:24:37Z 2025-07-15T08:24:37Z 2025-06-05 2025-07-10T13:42:52Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 2162-402X https://hdl.handle.net/2445/222243 40468805 eng Reproducció del document publicat a: https://doi.org/10.1080/2162402X.2025.2513109 OncoImmunology, 2025, vol. 14, num. 1 https://doi.org/10.1080/2162402X.2025.2513109 cc-by-nc (c) Sierra Rodero, Belén et al., 2025 http://creativecommons.org/licenses/by-nc/3.0/es/ info:eu-repo/semantics/openAccess 14 p. application/pdf Informa UK Limited Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))